2. China Biologic Products, Inc. (CBPO): Engages in the research, development, manufacturing, and sale of plasma-based pharmaceutical products. Market cap of $173.99M. RSI(14) at 37.14. Levered free cash flow/enterprise value at 15.16% (levered free cash flow at $17.88M and enterprise value at $117.96M). The stock is a short squeeze candidate, with a short float at 6.28% (equivalent to 44.65 days of average volume). The stock is currently stuck in a downtrend, trading 11.78% below its SMA20, 20.2% below its SMA50, and 47.87% below its SMA200. It's been a rough couple of days for the stock, losing 11.1% over the last week.
http://seekingalpha.com/article/296333-3-oversold-biotech-stocks-undervalued-by-levered-free-cash-flow?source=yahoo
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM